In addition, PD98059 and/or AZD1480 can reduce the PEAK1-enhanced migration, invasion and EMT of NSCLC cells, suggesting that targeting the ERK1/2 and JAK2 pathways could potentially be used to treat PEAK1-overexpressing lung cancer in combination with standard chemotherapy. This evidence concerns the gene JAK2 and non-small cell lung carcinoma.